AbCellera Biologics (ABCL) Free Cash Flow (2020 - 2026)
AbCellera Biologics (ABCL) posted Free Cash Flow of -$37.4 million for Q1 2026, up 16.22% on a QoQ basis from -$44.6 million in Q4 2025, and down 68.34% year-over-year from -$118.0 million in Q1 2025.
AbCellera Biologics (ABCL) Free Cash Flow (2020 - 2026) Analysis & Trends
AbCellera Biologics' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$37.4 million for Q1 2026.
- Quarterly Free Cash Flow fell 68.34% year-over-year to -$37.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$189.2 million (down 32.06% YoY) and the FY2025 annual result came in at -$174.1 million, up 6.89% from the prior year.
- Free Cash Flow was -$37.4 million for Q1 2026 at AbCellera Biologics, up from -$44.6 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $241.7 million in Q2 2022 and bottomed at -$139.3 million in Q3 2022.
- A 5-year average of -$18.4 million and a median of -$37.4 million in 2026 frame the typical range for Free Cash Flow.
- Peak annual rise in Free Cash Flow reached 171.08% in 2022, while the deepest fall reached 860.29% in 2022.
- AbCellera Biologics' Free Cash Flow stood at $18.6 million in 2022, then sank by 283.2% to -$34.0 million in 2023, then surged by 30.59% to -$23.6 million in 2024, then slumped by 88.68% to -$44.6 million in 2025, then grew by 16.22% to -$37.4 million in 2026.
- Business Quant data shows ABCL's Free Cash Flow at -$37.4 million in Q1 2026, -$44.6 million in Q4 2025, and -$61.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | AbCellera Biologics | 1.72 Bn | 1.72 Bn | - | -37.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.35 Mn |
| Mar 31, 2026 | -37.35 Mn |
| Dec 31, 2025 | -44.59 Mn |
| Dec 31, 2025 | -44.59 Mn |
| Sep 30, 2025 | -61.52 Mn |
| Sep 30, 2025 | -61.52 Mn |
| Jun 30, 2025 | -45.77 Mn |
| Jun 30, 2025 | -45.77 Mn |
| Mar 31, 2025 | -22.19 Mn |
| Mar 31, 2025 | -22.19 Mn |
| Dec 31, 2024 | -23.63 Mn |
| Dec 31, 2024 | -23.63 Mn |
| Sep 30, 2024 | -47.40 Mn |
| Sep 30, 2024 | -47.40 Mn |
| Jun 30, 2024 | -50.08 Mn |
| Jun 30, 2024 | -50.08 Mn |
| Mar 31, 2024 | -65.85 Mn |
| Mar 31, 2024 | -65.85 Mn |
| Dec 31, 2023 | -34.04 Mn |
| Dec 31, 2023 | -34.04 Mn |